Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Jefferies has raised its price target on Insulet Corporation (NASDAQ:PODD) to $375.00 from $360.00 while maintaining a Buy rating following the company’s strong second-quarter performance. Currently trading at $291.33, the stock sits within analysts’ target range of $260-$380, though InvestingPro analysis indicates the stock is fairly valued based on its proprietary Fair Value model.
Insulet reported second-quarter results that significantly exceeded market expectations, with sales reaching $649.1 million, representing 31% growth excluding foreign exchange effects, compared to consensus estimates of $614 million.
The company’s EBITDA for the quarter was $157.5 million, showing a 570 basis point year-over-year improvement and surpassing consensus expectations of $129.7 million.
Following these results, Insulet raised its full-year guidance across all metrics, now projecting revenue growth of 24-27%, up from its previous forecast of 19-22% and ahead of consensus estimates of 22%.
The company also increased its operating margin guidance to 17-17.5%, compared to its prior guidance of 16.5%, with Jefferies describing the quarterly performance as "outstanding."
In other recent news, Insulet Corporation reported strong second-quarter results for 2025, surpassing analysts’ expectations. The company announced earnings per share of $1.17, which was significantly higher than the projected $0.92, resulting in a 27.17% earnings surprise. Insulet’s revenue for the quarter reached $649 million, exceeding the anticipated $614.18 million and marking a 31% increase from the previous year. These results highlight the company’s robust financial performance and growth trajectory. Additionally, the earnings report contributed to a notable increase in the company’s stock price during pre-market trading. While the earnings and revenue figures were the main highlights, no recent mergers or acquisitions were reported. Analyst firms have yet to provide any new upgrades or downgrades following these results. These developments reflect Insulet’s strong position in the market as of the second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.